Position in CNTA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Common Shares in CNTA Over Time
Shares Held
Position Value (USD)
Derivatives in CNTA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$0
PutShares
40,500
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
637,994 | $24,690,367 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
38,698 | $11,649,258 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
427,321 | $10,289,889 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
601,972 | $8,132,641 | |
| 5 | ARDX |
Ardelyx, Inc.
|
1,579,828 | $8,057,122 | |
| 6 | URGN |
UroGen Pharma Ltd.
|
212,775 | $7,830,120 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,311 | $6,115,243 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
112,129 | $5,690,546 |
All Filings in CNTA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 40,500 | Put | Sole | 2026-05-15 | |
| 2025-09-30 | — | 13,105 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | — | 33,184 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | — | 136,674 | Shares | Sole | 2025-05-15 | |
| 2025-03-31 | — | 94,600 | Put | Sole | 2025-05-15 | |
| 2024-12-31 | — | 164,703 | Shares | Sole | 2025-02-14 | |
| 2024-12-31 | — | 67,700 | Put | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||